Authors: Qader Motarjemizadeh Naser Samadi Aidenloo Siamak Sepehri
Publish Date: 2015/05/06
Volume: 36, Issue: 1, Pages: 63-71
Abstract
The present study was undertaken to compare the pterygium recurrence rates after treatment with two different concentrations of topical bevacizumab in those who had undergone a primary pterygium excision The 90 patients who underwent pterygium excision were enrolled in this prospective placebocontrolled doubleblinded interventional case series The participants were randomly categorized into 3 groups each consisting of 30 subjects 24 h after surgery Group II and Group III received a total of 5 and 10 mg/mL dose of topical bevacizumab respectively whereas patients in Group I were administered only a placebo starting a day after surgery Participants were instructed to instill their topical medicines 4 times a day for 1 week The patients were examined for pterygium recurrence and complications at postoperative 1 7 and 14 days as well as each month during the following year Pterygia recurred in 14 patients 467 in Group I and in 4 patients 133 in Group II No recurrence was observed in Group III during the followup period The Kaplan–Meier survival analysis disclosed a significantly better outcome for those who had been treated with 10 mg/mL concentrations of bevacizumab Mantel–Cox log rank analysis P 0001 The mean recurrence time was not significantly different between Group I and Group II No ocular or systemic complication developed till the end of followup Thus 10 mg/mL concentration of topical bevacizumab was more efficacious than 5 mg/mL dose in preventing pterygium recurrenceAll procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards
Keywords: